Fig. 2 | Scientific Reports

Fig. 2

From: Multicenter randomized trial assessing efficacy and safety of aerosolized dornase Alfa in COVID-19 ARDS

Fig. 2

Impact of in vivo DNAse administration on NET levels (A) and DNAse activity (B) in Plasma. Comparison of DNAse-treated (blue) and control (black) patients at Day 0, Day 2, Day 7, and Day 28. Both treated patients and controls showed a trend of increasing NET levels in plasma between J0 and J7 (p = 0.71 and p = 0.11 respectively), which subsequently dropped at J28 (p = 0.38 and p = 0.22, respectively). However, DNAse-treated patients did not exhibit lower plasma NET formation compared to controls. DNAse activity was not significantly augmented in plasma of treated patients compared to controls.

Back to article page